Preoperative Chemoradiotherapy With CApecitabine and Temozolomide in MGMT Silenced, MSS, Locally Advanced RecTal Cancer

Preoperative Chemoradiotherapy With CApecitabine and Temozolomide in MGMT Silenced, MSS, Locally Advanced RecTal Cancer is a phase 2, interventional study registered as NCT05136326 by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, with a registry enrolment figure of 21 participants, started 2021-12-01 and due to reach its primary completion in 2023-12. Interventions recorded: External-beam radiation; Capecitabine; Temozolomide. Conditions listed: Rectal Cancer. Primary outcome: To evaluate the rate of complete pathologic response (pCR). Colorectal eligibility wording from the registry: "* Histologically confirmed diagnosis of rectal adenocarcinoma, with centrally confirmed mismatch repair proficiency (MSS) by PCR, lack of MGMT expression by IHC and MGMT promoter methylation by pyrosequencing;". Sites: Italy. No results are recorded here; the registry entry is the source.